Duloxetine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Duloxetine: From Depression/Anxiety Disorders to Obsessive-Compulsive Disorder
One-Sentence Summary
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI); formal original-indication records in this evidence pack are unavailable, but literature within the pack confirms established use in major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain (PMID 31749717). Among 10 TxGNN-predicted indications reviewed, Obsessive-Compulsive Disorder (OCD) is the only candidate with meaningful clinical and literature support — 5 clinical trials (including a completed Phase 4 efficacy trial and a double-blind RCT on augmentation) and 20 publications — while the other 9 candidates (including the top-ranked TxGNN score) lack any supporting evidence and are held.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded (data gap); per in-pack literature, duloxetine (SNRI) is established for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain (PMID 31749717) |
| Predicted New Indication | Obsessive-Compulsive Disorder (OCD) |
| TxGNN Prediction Score | 99.84% (rank 2195) |
| Evidence Level | L2 |
| Finland Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed formal mechanism-of-action documentation is not available in this evidence pack (data gap). Based on known information, duloxetine is a dual serotonin-norepinephrine reuptake inhibitor (SNRI), and its efficacy in depression and anxiety-spectrum disorders is well established.
OCD's pathophysiology is closely linked to serotonergic dysregulation within the cortico-striato-thalamo-cortical circuit. SSRIs are already first-line pharmacotherapy for OCD, and SNRIs such as venlafaxine have documented use as alternatives in treatment-resistant cases. Duloxetine's serotonergic and noradrenergic reuptake inhibition therefore has a biologically plausible extension into OCD, particularly as an augmentation strategy in patients who do not fully respond to SSRIs.
This mechanistic plausibility is reinforced by a directly relevant completed Phase 4 trial and a double-blind RCT on duloxetine augmentation in resistant OCD (see below), which together elevate this candidate from a pure model prediction (L5) to L2 evidence — the strongest-supported candidate among all 10 TxGNN predictions reviewed for this drug.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00464698 | Phase 4 | Completed | 20 | Directly assesses duloxetine's efficacy in treating OCD; most relevant trial (relevance grade A). |
| NCT01404871 | N/A | Completed | 26 | Compares clomipramine, escitalopram, and duloxetine to predict individual medication response in OCD (grade B). |
| NCT02476136 | N/A | Unknown | 8,800 | Individual-patient-data meta-analysis of antidepressant efficacy across anxiety disorders (including OCD) by baseline severity (grade B). |
| NCT01944657 | N/A | Withdrawn | 0 | TMS vs. medication monotherapy for major depression; withdrawn (N=0), low relevance to OCD (grade C). |
| NCT05930912 | N/A | Unknown | 1 | Psychoanalytic case study in ASD with comorbid OCD; single-subject, low relevance (grade C). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27811556 | 2016 | RCT | J Clin Psychopharmacol | Double-blind controlled trial evaluating duloxetine augmentation in treatment-resistant OCD. |
| 25637377 | 2015 | Open-label | Int J Neuropsychopharmacol | Open-label study investigating duloxetine efficacy for OCD (DSM-IV). |
| 28477500 | 2017 | Review/Meta-analysis | J Affect Disord | Meta-analysis showing OCD has a reduced placebo and antidepressant response vs. other anxiety disorders. |
| 32982805 | 2020 | Review | Front Psychiatry | Meta-review of antidepressant efficacy, tolerability, and suicidality in children/adolescents, covering OCD. |
| 31749717 | 2019 | Review | Front Psychiatry | Systematic review of duloxetine use across psychiatric disorders beyond depression/GAD, including OCD. |
| 24766145 | 2014 | Review | Expert Opin Pharmacother | Updated review of serotonergic antidepressants (including duloxetine) in OCD treatment. |
| 16669725 | 2006 | Review | J Clin Psychiatry | Critical review of SNRIs (venlafaxine, clomipramine) as alternatives to SSRIs in OCD. |
| 39583807 | 2024 | Review | Heliyon | Machine-learning classification of OCD medication response patterns. |
| 39735048 | 2024 | Case report | Cureus | Supratherapeutic duloxetine combined with CBT in severe treatment-resistant OCD with comorbid depression. |
| 22567604 | 2012 | Case report | Innov Clin Neurosci | Suprathreshold duloxetine used for treatment-resistant depression, binge-purging anorexia, and OCD. |
Finland Market Information
Duloxetine currently has no marketing authorization on record in Finland (0 authorizations; market status: 未上市/not marketed). No product/dosage-form data is available to tabulate.
Other TxGNN Predictions Reviewed (Not Prioritized)
| Disease | TxGNN Score | Evidence Level | Decision | Reason |
|---|---|---|---|---|
| Benign paroxysmal torticollis of infancy | 99.85% | L5 | Hold | No mechanistic link, no pediatric safety data, no trials/literature — likely model noise. |
| Agoraphobia | 99.84% | L3 | Research Question | Literature exists for panic disorder generally, but no agoraphobia-specific trial evidence. |
| Paranoid personality disorder | 99.78% | L5 | Hold | No mechanistic basis (personality structure, not monoamine pathology); no evidence. |
| Schizotypal personality disorder | 99.78% | L5 | Hold | Same as above. |
| Histrionic personality disorder | 99.78% | L5 | Hold | Same as above. |
| Schizoid personality disorder | 99.78% | L5 | Hold | Same as above. |
| Ohdo syndrome and variants | 99.69% | L5 | Hold | Rare genetic syndrome (KAT6A/KAT6B); no pharmacological relevance. |
| Ligneous conjunctivitis | 99.66% | L5 | Hold | Rare plasminogen-deficiency eye disease; no pharmacological relevance. |
| Blepharophimosis–intellectual disability syndrome (Ohdo type) | 99.60% | L5 | Hold | Rare genetic syndrome; no pharmacological relevance. |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Among 10 TxGNN-predicted indications, OCD is the only one with converging supportive evidence — a completed Phase 4 efficacy trial, a double-blind RCT on augmentation therapy, and a serotonergic mechanistic rationale consistent with established OCD pharmacotherapy. However, trials are small-scale and largely positioned as augmentation rather than monotherapy, and duloxetine currently has no market authorization in Finland.
To proceed, the following is needed:
- TFDA/Fimea package insert with warnings, contraindications, and DDI data (currently a blocking data gap, DG001)
- Confirmed mechanism-of-action documentation from DrugBank (DG002)
- Larger controlled trials specifically evaluating duloxetine for OCD (as monotherapy or augmentation) beyond the existing N=20/N=26 studies
- Finland-specific regulatory pathway assessment, given the drug is not currently marketed there
- No further investment recommended for the remaining 9 predicted indications absent new trial or literature evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.